DOCSLIB.ORG

Amyloid: Insoluble, but Solvable

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Amyloid: Insoluble, but Solvable XIVth International Symposium on Amyloidosis Amyloid: Insoluble, but Solvable April 27 – May 1, 2014 Indianapolis, IN, USA JW Marriott Amyloid: Insoluble, but Solvable XIVth International Symposium on Amyloidosis April 27 – May 1, 2014 Indianapolis, Indiana, USA The sculpture is located in the Morris Mills Atrium of the VanNuys Medical Science Building (home of the Amyloid Research Center), Indiana University School of Medicine. DNA Tower, 20.2 feet (6.2 m) tall and 4.7 feet (1.4 m) in diameter, is composed of 1,200 blown- glass globes and weighs 3,000 pounds. Each globe has a different texture and weighs between 1 and 2 pounds. Mauve, green and blue globes represent the four nitrogenous bases, while yellow globes represent the sugar- phosphate backbone. The glass is held in place by a steel armature. The support of the sculpture is protected by a circular cherry wood base. The sculpture was dedicated in 2003 and commissioned to commemorate both the 100th anniversary of the Indiana University School of Medicine (founded in 2003) and the 50th anniversary of the discovery of the structure of the DNA molecule (discovered 1953) by Indiana University alumnus James D. Watson and his colleague Francis Crick. DNA Tower, a sculpture by American glass artist Dale Chiluly Table of Contents Acknowledgements --------------------------------------------------------------------------------------------------- 3 Welcome Address ----------------------------------------------------------------------------------------------------- 4 Organizing Committee and Faculty ------------------------------------------------------------------------------- 5 Scientific Presentation Instructions ------------------------------------------------------------------------------- 6 General Information -------------------------------------------------------------------------------------------------- 7 Instructions for Evening Events ------------------------------------------------------------------------------------ 8 Maps --------------------------------------------------------------------------------------------------------------------- 9 Symposium Schedule ----------------------------------------------------------------------------------------------- 11 Monday, April 28, 2014 Plenary Session 1 Abstracts (OP-1 – OP-6) --------------------------------------------------------- 20 Plenary Session 2 Abstracts OP-7 – OP-12) --------------------------------------------------------- 25 Plenary Session 3 Abstracts (OP-13 – OP-20) ------------------------------------------------------ 30 Tuesday, April 29, 2014 Plenary Session 4 Abstracts (OP-21 – OP-30) ------------------------------------------------------ 39 Plenary Session 5 Abstracts (OP-31 – OP-36) ------------------------------------------------------ 49 Plenary Session 6 Abstracts (OP-37 – OP-46) ------------------------------------------------------ 55 Wednesday, April 29, 2014 Plenary Session 7 Abstracts (OP- 47 – OP-52) ---------------------------------------------------- 66 Plenary Session 8 Abstracts (OP-53 – OP-58) ----------------------------------------------------- 72 Plenary Session 9 Abstracts (OP -59 – OP-64) ---------------------------------------------------- 78 Plenary Session 10 Abstracts (OP-65 – OP-72) --------------------------------------------------- 84 Thursday, May 1, 2014 Plenary Session 11 Abstracts (OP-73 – OP-78) ---------------------------------------------------- 92 Plenary Session 12 Abstracts (OP-79 – OP-84) ---------------------------------------------------- 97 Poster List for Monday, April 28, 2014 ----------------------------------------------------------------------- 103 Monday Poster Abstracts (PA-1 – PA-52) -------------------------------------------------------------------- 106 Poster List for Tuesday, April 29, 2014 ----------------------------------------------------------------------- 151 Tuesday Poster Abstracts (PB-1 – PB-54) -------------------------------------------------------------------- 154 Poster list for Wednesday, April 30, 2014 ------------------------------------------------------------------- 210 Wednesday Poster Abstracts (PC-1 – PC-56) ---------------------------------------------------------------- 213 Presenting Author Index ----------------------------------------------------------------------------------------- 268 Acknowledgements The Organizing Committee of the XIVth International Symposium on Amyloidosis is grateful to the following sponsors whose generous contributions made the Symposium possible. Platinum Premier Sponsor Pfizer Platinum Sponsor Celgene Gold Sponsor Millennium Silver Sponsors Alnylam The Binding Site Bronze Sponsors Auven Therapeutics International Society of Amyloidosis ISIS Pharmaceuticals Onyx Prothena Grants & Scholarships Amyloidosis Foundation National Institute of Diabetes and Digestive and Kidney Diseases National Institute on Aging National Center for Advancing Translational Sciences – NIH Office of Rare Diseases Research 3 ISA . INTERNATIONAL SOCIETY OF AMYLOIDOSIS WELCOME ADDRESS Dear Friends, Colleagues, and All interested in the Amyloidoses: On behalf of the Organizing Committees I welcome you to Indianapolis and the XIVth International Symposium on Amyloidosis. This is the 5th International Symposium that we have had in what we have been known to call “the new world”. We hope to maintain the high quality of all the previous Symposia. I started attending the International Symposia in 1979 when it was held in Póvoa de Varzim, Portugal. I found that Symposium and all of the subsequent Symposia very rewarding both scientifically and socially. While it has been only two years since our last Symposium (Groningen, 2012) a great amount of new data on many types of amyloidosis will be ready for discussion at the present scientific meeting. A major objective of the present symposium is to foster greater interaction between those scientists and physicians with interest in all three of the major amyloidoses, AL, AA, and Hereditary. The number and quality of abstracts submitted for the XIVth International Symposium on Amyloidosis assure us this will be a very successful meeting. The increasing number of young investigators encourages us as we think about future directions of our Society. Success of this Symposium will in large-part be due to generous sponsorship from a number of pharmaceutical companies as well as financial support from the International Society of Amyloidosis, The Amyloidosis Foundation, and National Institutes of Health (NIDDK, NIA, and office of Rare Diseases). We have been very fortunate to have an effective and dedicated staff for organizing this Symposium. The final answer is still not in but I am certain we will have an excellent Symposium and we will all go home with new thoughts, projects and aspirations about the advancement of research on the amyloidoses. With all good wishes for a pleasant stay in Indianapolis, Merrill D. Benson, M.D. President 4 Organizing Committee and Faculty International Society of Amyloidosis Board Merrill D. Benson - President and Host of the XIVth International Symposium on Amyloidosis, Indianapolis, USA Martha Skinner - Immediate Past President, Boston, USA Bouke P. C. Hazenberg - Vice President and President-Elect, Groningen, the Netherlands Laura Obici - Secretary, Pavia, Italy Angela Dispenzieri - Treasurer, Rochester, USA Per Westermark - Editor-in-Chief of Amyloid, Uppsala, Sweden Giovannni Palladini - Member-at-Large, Pavia, Italy David C. Seldin - Member-at-Large, Boston, USA Yukio Ando - Member-at-Large, Kumamoto, Japan International Committee Joel N. Buxbaum, La Jolla, USA Bo-Goran Ericzon, Stockholm, Sweden Morie A. Gertz, Rochester, USA Gilles Grateau, Paris, France Philip N. Hawkins, London, UK Shu-Ichi Ikeda, Matsumoto, Japan Robert Kisilevsky, Ontario, Canada Robert Kyle, Rochester, USA Reinhold P. Linke, Martinsreid, Germany Avi Livneh, Tel-Hashomer, Israel Giampaolo Merlini, Pavia, Italy Maria J. Saraiva, Porto, Portugal Ole B. Suhr, Umea, Sweden Local Committee Rafat Abonour Jeffrey Breall Oscar W. Cummings Bernardino Ghetti Barbara Kluve-Beckerman Juris J. Liepnieks Jill R. Murrell Ann-Danh T. Phan Carrie Phillips Maria Picken G. David Roodman Ruben Vidal 5 Scientific Presentation Instructions Oral presentations: x Oral presentations are limited to 15 minutes = no more than 10 minutes for presentation and 5 minutes for discussion. x Presentations should be in PowerPoint and stored on a USB flash drive. x The preview area is Room 311 – across the hall from Grand Ballroom 5. A media tech will be available for help and will provide additional instructions. x Speakers should bring their presentations to the preview room 1 hour before the beginning of the session. x Please include the abstract number and presenter’s name in the PowerPoint file name. x All data will be handled responsibly and deleted after the presentation. x The speaker of the oral presentation must be registered for the Symposium. Poster presentations: x Posters are identified by PA (Monday), PB (Tuesday), or PC (Wednesday) followed by the number of the board. x All posters will be presented in Griffin Hall on Level 2 of the JW Marriott Hotel. x The size of the poster board is 4 feet high and 8 feet wide. Posters must fit into this format. x Posters should be mounted preferably before the program starts at 8:00 am and no later than 15 minutes before the start of the lunch-time poster session. x The presenter should be near his/her poster during the late afternoon session. x Posters need to
Load more

Recommended publications
  • BIO-2005-MK-ONLINE (Page 1)
    THE SCIENCE. THE BUSINESS. THE WORLD OF BIOPHARMACEUTICALS. 2005 MEDIA PLANNER www.biopharminternational.com THE PRINT-BASED MARKETING Display Advertising BIOPHARM The foundation of any b-to-b marketing program, print advertising allows you to BRAND touch 29,200 BPA-qualified subscribers* with your brand or product message. BioPharm International’s Build your marketing plan around the message portfolio of products allows conveyed in your print ad and utilize other channels you to reach our highly to further reinforce your message. desirable audience through multiple marketing channels. Custom Publishing Work with us to write and design a custom white paper or article Studies show integrated published as an advertorial in the pages of BioPharm. marketing is the key to successfully delivering your Insert A unique way to deliver white papers, brochures or any other collateral message to today’s buyer. material to our readers. Reinforce your message to the most important audience Polybag in your market—ask your Talk about premium placement! Send your printed piece as a ride-along advertising sales manager and readers will get the message as soon as the issue hits their desk. to design an integrated program Direct Mail utilizing the channels that best Planning a direct mail campaign to reinforce your ad message? meet your marketing objectives. Rent our list to ensure your marketing material reaches your most important audience. Post-It Note A truly unique way to send your message to our readers, Post-It Notes serve as front cover reminders about your brand. Use Post-Its to call out your ads in the issue or run 6 or 12 Post-It Notes for a truly unique campaign.
    [Show full text]
  • Breaking Eroom's
    Breaking Eroom’s Law Michael S. Ringel, Jack W. Scannell, Mathias Baedeker and Ulrik Schulze https://doi.org/10.1038/d41573-020-00059-3 Supplementary Box 1 | Data and analysis Breaking Eroom’s Law The count and value of NMEs relative to R&D spend comes from BCG’s New Therapeutic Drug (NTD) Database, which is also the source of BCG’s annual publication in Nat. Rev. Drug. Discov. showing trends in count and value over time.1 FDA approvals are from FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER),2 peak sales estimates are from EvaluatePharma®,3 and R&D spend data are from BCG Value Science, inflation-adjusted using the standard global GDP-based inflator from the Economist Intelligence Unit.4 For additional details on methodology, see Schulze, Baedeker, Chen and Greber.5 Eroom’s Law is linear on a log scale through 2010, with an average increase approximately 12% per annum, or a halving of productivity approximately every seven years. If this holds true even after 2010, we would see a continuation of the linear development of the number of drugs approved per billion US$ R&D spending when using a logarithmic scale. To demonstrate that the deviation from regression after 2010 is statistically relevant we assumed the following: 1) Eroom's law is true up to 2010. 2) Eroom's law is not true between 2010 and 2018. To confirm our assumptions, we used a log-linear regression to describe the number of new molecular entities (NMEs) approved by the US FDA per billion US$ R&D spending from 1950–2010.
    [Show full text]
  • List of Section 13F Securities
    List of Section 13F Securities 1st Quarter FY 2004 Copyright (c) 2004 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2004, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2004. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by Section 13(f)(1) and Rule 13f-1 thereunder.
    [Show full text]
  • Promotion and Development Collaborations Between Established Players
    Promotion and Development Collaborations Between Established Players Randall B. Sunberg Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements October 21-22, 2002 1 www.morganlewis.com MorganMorgan Lewis:Lewis: LifeLife SciencesSciences FocusFocus • Founded in 1873, today 1,100 lawyers in 13 offices worldwide • 175 Life Sciences professionals, including 90 with advanced degrees ranging from biochemistry to molecular genetics to immunology • Interdisciplinary coordination of transactions, IP, litigation, FDA and antitrust expertise to meet our clients’ strategic objectives • Recently ranked as the 5th leading transactional law firm in the nation by The American Lawyer "Corporate Scorecard” • Named by many Fortune 250 companies as one of their primary law firms • Recognized by corporate counsel for exceptional client service in a survey of Fortune 1000 companies • Featured prominently in the annual National Law Journal survey of “Who Defends Corporate America” 2 MorganMorgan Lewis:Lewis: RecentRecent LifeLife SciencesSciences DealsDeals • Aventis - Genta collaboration for co-development and commercialization of Genasense™ • Enzon - Elan acquisition of Abelcet® product rights and manufacturing assets • Quintiles - Eli Lilly co-promotion and marketing collaboration for Cymbalta™ • Adolor - GlaxoSmithKline development and commercialization collaboration for Alvimopan™ • Arena Pharmaceuticals - Merck drug discovery collaboration • Cephalon - Anesta stock-for-stock public company acquisition • Aventis - Millennium alliance
    [Show full text]
  • THE TRUSTEES of INDIANA UNIVERSITY (CUSIP6: 455167) Annual Disclosure Document December 2008
    THE TRUSTEES of INDIANA UNIVERSITY (CUSIP6: 455167) Annual Disclosure Document December 2008 Relating to the following bond issues occurring in the month and year specified: Indiana University Student Fee Bonds, Series K: August 1995 Indiana University Student Fee Bonds, Series L: April 1998 Indiana University Student Fee Bonds, Series M: December 1999 Indiana University Student Fee Bonds, Series N: June 2001 Indiana University Student Fee Bonds, Series O: March 2003 Indiana University Certificates of Participation, Series 2003A: April 2003 Indiana University Student Fee Bonds, Series P: December 2004 Indiana University Student Fee Bonds, Series Q: June 2006 Indiana University Student Fee Bonds, Series R: June 2006 Indiana University Student Fee Bonds, Series S: February 2008 Indiana University Facility Revenue Bonds, Series 1994A: May 1994 Indiana University Student Residence System Bonds, Series 2004B: June 2004 Indiana University Facility Revenue System Bonds, Series 2004: July 2004 Indiana University Consolidated Revenue Bonds, Series 2008A: February 2008 Exhibit A - Audited Financial Statements for the Fiscal Year Ended June 30, 2008 Exhibit B - Certificate RE: Audited Financial Statements Schedule I to Exhibit B Exhibit C - Certificate RE: Annual Financial Information Disclosure INDIANA UNIVERSITY General Indiana University (the “University”) is one of the largest universities in the nation. It was established by the Indiana General Assembly in 1820 as Indiana Seminary and was located in Bloomington. It was designated as Indiana College by the General Assembly in 1828 and became Indiana University in 1838. Indiana University is composed of eight campuses, with core campuses in Bloomington and Indianapolis and regional campuses serving other areas of the state located in Gary (Northwest), Fort Wayne (Indiana University Purdue University Fort Wayne), Kokomo, New Albany (Southeast), Richmond (East), and South Bend.
    [Show full text]
  • The Bottom 99
    The Top 100 June 1, 2004 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. ABFI AMER BUSINESS FINL SVCS INC Financials ABGX ABGENIX INC Health Care ADLR ADOLOR CORP Health Care AGEN ANTIGENICS INC/DEL Health Care AGI ALLIANCE GAMING CORP Consumer Cyclicals AKLM ACCLAIM ENMNT INC Technology ALKS ALKERMES INC Health Care ALXN ALEXION PHARMACEUTICALS INC Health Care AMLN AMYLIN PHARMACEUTICALS INC Health Care APHT APHTON CORP Health Care ARNA ARENA PHARMACEUTICALS INC Health Care BIOV BIOVERIS CORP Health Care BMRN BIOMARIN PHARMACEUTICAL INC Health Care BVSN BROADVISION INC Technology CBRX COLUMBIA LABORATORIES INC Health Care CCRD CONCORD COMMUNICATIONS INC Technology CDE COEUR D'ALENE MINES CORP Basic Materials CFFN CAPITOL FEDERAL FINANCIAL Financials COMS 3COM CORP Technology CPN CALPINE CORP Utilities CRAY CRAY INC Technology CRGN CURAGEN CORP Health Care CRXA CORIXA CORP Health Care CYBX CYBERONICS INC Health Care DAL DELTA AIR LINES INC Capital Goods DEPO DEPOMED INC Health Care DMX I-TRAX INC Health Care DRXR DREXLER TECHNOLOGY CORP Technology DSCO DISCOVERY LABORATORIES INC Health Care DV DEVRY INC Capital Goods ELGX ENDOLOGIX INC Health Care EPIX EPIX MEDICAL INC Health Care EXEL EXELIXIS INC Health Care EXLT EXULT INC Capital Goods FCP FALCON PRODUCTS INC Capital Goods FMKT FREEMARKETS INC Technology FXEN FX ENERGY INC Energy GBTVK GRANITE BROADCASTING Consumer Cyclicals GENE OSCIENT PHARMACEUTICALS CORP Health Care GGNS GENUS INC Technology GLFD GUILFORD PHARMACEUTICAL INC Health Care GMRK GULFMARK OFFSHORE
    [Show full text]
  • Pierre Cremieux October 2020 CV (English)
    PIERRE-YVES CREMIEUX, PH.D. President Office: 617 425 8135 111 Huntington Avenue Fax: 617 425 8001 14th Floor [email protected] Boston, MA 02199 Pierre-Yves Cremieux, President of Analysis Group, has a broad range of expertise in health economics, antitrust, statistics, and labor economics. He has consulted to numerous clients in the United States and Canada and testified in bench and jury trials, arbitrations, and administrative proceedings. Dr. Cremieux has served as an expert and supported other experts in both litigation and non-litigation matters on antitrust issues; general commercial claims; contractual disputes; and a number of labor- related matters in a variety of industries, including high tech, pharmaceuticals, biotech, financial products, consumer products, and commodities. He has assessed the evaluation of damages on a class-wide basis in some of the largest class action matters in recent years. His scientific research in antitrust economics, class certification, health economics, and statistics has been published in numerous peer-reviewed journals, including the George Mason Law Review, the American Bar Association Economics Committee Newsletter, The Review of Economics and Statistics, the Journal of Health Economics, Industrial and Labor Relations Review, the Journal of Clinical Oncology, and The American Journal of Managed Care. Dr. Cremieux’s research has been cited in leading media outlets including The Wall Street Journal and Forbes. Dr. Cremieux has frequently presented at leading legal, health care, and economics seminars on topics such as antitrust, class certification, health economics, and statistics, in both the United States and Canada. He has also been invited to teach courses on economics, statistics, health care, and antitrust at various schools including McGill University, Boston University, Harvard Medical School, and the Yale School of Management.
    [Show full text]
  • Accelerator – Sept2015
    The Accelerator INDIANA SECTION OF THE AMERICAN CHEMICAL SOCIETY SEPTEMBER, 2015 Best wishes to all Chair’s Corner BY MATT GARDLIK The Indiana Local join us for a lunch reception with many Section continues to giveaways for those in attendance. gain momentum on In November, the section will be celebrating the local level as well National Chemistry Week with activities at as the national level. the Indianapolis Children's Museum. The theme for this year's NCW is "Chemistry As you may know, Colors Our World." We'll host interesting our Section is now a demonstrations for young scientists involving large section, which chemistry, and enjoy the afternoon at the means that we will be voting this year to elect museum. an additional Councilor to represent the section at the National Level. Hope to see you there! At the recent National Meeting in Boston, the Indiana Local Section won three ChemLuminary awards: A Special Thank You to Outstanding Continuing Public Relations Program of a Local Section Outstanding or Creative Local Section The activities that the Indiana Section Younger Chemists Committee Event of the ACS helps to organize and participate in would not be possible Outstanding On-going NCW Event without the support of our members, More information on the ChemLuminary awards is employers, and business community. discussed on page 5. The section recently received a $10,000 Celebrate Science Indiana will take place on donation from Dow AgroSciences. This October 3rd at the Indiana State donation will help to support the Fairgrounds. CSI will host chemistry teachers activities mentioned above as well as and engage them in the newly-formed many others.
    [Show full text]
  • The Regental Laureates Distinguished Presidential
    REPORT TO CONTRIBUTORS Explore the highlights of this year’s report and learn more about how your generosity is making an impact on Washington and the world. CONTRIBUTOR LISTS (click to view) • The Regental Laureates • Henry Suzzallo Society • The Distinguished Presidential Laureates • The President’s Club • The Presidential Laureates • The President’s Club Young Leaders • The Laureates • The Benefactors THE REGENTAL LAUREATES INDIVIDUALS & ORGANIZATIONS / Lifetime giving totaling $100 million and above With their unparalleled philanthropic vision, our Regental Laureates propel the University of Washington forward — raising its profile, broadening its reach and advancing its mission around the world. Acknowledgement of the Regental Laureates can also be found on our donor wall in Suzzallo Library. Paul G. Allen & The Paul G. Allen Family Foundation Bill & Melinda Gates Bill & Melinda Gates Foundation Microsoft DISTINGUISHED PRESIDENTIAL LAUREATES INDIVIDUALS & ORGANIZATIONS / Lifetime giving totaling $50 million to $99,999,999 Through groundbreaking contributions, our Distinguished Presidential Laureates profoundly alter the landscape of the University of Washington and the people it serves. Distinguished Presidential Laureates are listed in alphabetical order. Donors who have asked to be anonymous are not included in the listing. Acknowledgement of the Distinguished Presidential Laureates can also be found on our donor wall in Suzzallo Library. American Heart Association The Ballmer Group Boeing The Foster Foundation Jack MacDonald* Robert Wood Johnson Foundation Washington Research Foundation * = Deceased Bold Type Indicates donor reached giving level in fiscal year 2016–2017 1 THE PRESIDENTIAL LAUREATES INDIVIDUALS & ORGANIZATIONS / Lifetime giving totaling $10 million to $49,999,999 By matching dreams with support, Presidential Laureates further enrich the University of Washington’s top-ranked programs and elevate emerging disciplines to new heights.
    [Show full text]
  • Has Announced the Appointment of Christian Burks As Chief Scientific
    PEOPLE Affinium Pharmaceuticals (Toronto, Ontario, joined the company as senior vice president, Canada) has announced the appointment of research and preclinical development. Dr. Christian Burks as chief scientific officer. Dr. Miletich was most recently senior vice presi- Burks was most recently vice president and dent for worldwide preclinical development chief informatics officer at Exelixis. at Merck Research Laboratories. OXiGENE (Watertown, MA) has appointed Gilead Sciences (Foster City, CA) has named Frederick Driscoll as CEO, replacing Bjorn John F. Milligan senior vice president and Nordenvall. Dr. Nordenvall will remain on CFO. Dr. Milligan joined Gilead in 1990 and the board of directors as vice chairman and served most recently as vice president, cor- serve as a strategic consultant to the compa- porate development. Sharon Surrey- ny. Prior to joining OXiGENE as president Barbari, who joined Gilead in 1998 and has and CFO in October 2000, Mr. Driscoll served as vice president and CFO since served as senior vice president of finance and February 2000, has announced her resigna- operations at Collagenesis. tion from the company. CuraGen (New Haven, CT) has announced Orchid BioSciences (Princeton, NJ) has the elections of David R. Ebsworth and John appointed Kenneth D. Noonan to its board H. Forsgren to its board of directors. Dr. of directors to replace Anne VanLent, who Ebsworth was formerly president and gener- resigned in 2001. Dr. Noonan is a partner at al manager of the pharmaceutical business LEK Consulting and leads the firm’s life sci- group for Bayer AG, and Mr. Forsgren is vice ences practice in the UK and Europe.
    [Show full text]
  • The Bottom 99
    The Top 100 December 1, 2003 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. ABFI AMER BUSINESS FINL SVCS INC Financials Thrifts & Mortgage Finance ABGX ABGENIX INC Health Care Biotechnology AGEN ANTIGENICS INC/DEL Health Care Pharmaceuticals AGIX ATHEROGENICS INC Health Care Pharmaceuticals ALKS ALKERMES INC Health Care Biotechnology ALXN ALEXION PHARMACEUTICALS INC Health Care Biotechnology AMLN AMYLIN PHARMACEUTICALS INC Health Care Biotechnology AMR AMR CORP/DE Industrials Airlines APHT APHTON CORP Health Care Biotechnology ARRY ARRAY BIOPHARMA INC Health Care Biotechnology ATW ATWOOD OCEANICS Energy Oil & Gas Drilling AVII AVI BIOPHARMA INC Health Care Biotechnology BEAV BE AEROSPACE INC Industrials Aerospace & Defense BFD BOSTONFED BANCORP INC Financials Thrifts & Mortgage Finance BPUR BIOPURE CORP Health Care Biotechnology BVSN BROADVISION INC Information Technology Internet Software & Services CBST CUBIST PHARMACEUTICALS INC Health Care Biotechnology CHPC CHIPPAC INC Information Technology Semiconductors CLHB CLEAN HARBORS INC Industrials Environmental Services CPTS CONCEPTUS INC Health Care Health Care Equipment CRGN CURAGEN CORP Health Care Biotechnology CRXA CORIXA CORP Health Care Biotechnology CTIC CELL THERAPEUTICS INC Health Care Biotechnology CVC CABLEVISION SYS CORP -CL A Consumer Discretionary Broadcasting & Cable TV CVTX CV THERAPEUTICS INC Health Care Biotechnology CYMI CYMER INC Information Technology Semiconductor Equipment DMI DEPOMED INC Health Care Pharmaceuticals DNDN DENDREON CORP Health
    [Show full text]
  • Table of Contents
    Table of contents Executive Summary Chapter 1 – Introduction Chapter 2 – Trends in drug delivery dealmaking 2.1. Introduction 2.2. Drug delivery partnering over the years 2.3. Bigpharma drug delivery dealmaking activity 2.4. Big biotech drug delivery dealmaking activity 2.5. Most active drug delivery dealmakers 2.6 Drug delivery partnering by deal type 2.7. Drug delivery partnering by disease type 2.8. Partnering by drug delivery technology type 2.9. Average deal terms for drug delivery partnering 2.9.1 Drug delivery headline values 2.9.2 Drug delivery upfront payments 2.9.3 Drug delivery milestone payments 2.9.4 Drug delivery royalty rates 2.10. The anatomy of drug delivery partnering 2.11. Drug delivery or specialty pharma? 2.11.1. Is specialty pharma the only way for drug delivery? 2.11.2. Best practice for optimizing drug delivery program development 2.11.3. The anatomy of a drug delivery deal 2.11.3.a. Case study 1: Alpharma – Durect 2.11.3.b. Case study 2: Bayer – MDRNA 2.11.3.c. Case study 3: Endo Pharmaceuticals – BioDelivery Sciences Chapter 3 – Leading drug delivery deals 3.1. Introduction 3.2. Top drug delivery deals by value Chapter 4 – Bigpharma drug delivery deals 4.1. Introduction 4.2. How to use bigpharma drug delivery partnering deals 4.3. Big pharma drug delivery partnering company profiles Abbott Actavis Inc (formerly Watson Pharmaceuticals) Actavis (merged with Watson Pharmaceuticals Oct 2012) Actelion Allergan Amgen Astellas AstraZeneca Baxter International Bayer Biogen Idec Boehringer Ingelheim Bristol-Myers Squibb Celgene CSL Daiichi Sankyo Dainippon Sumitomo Eisai Eli Lilly Endo Pharmaceuticals Forest Laboratories Galderma Gilead Sciences GlaxoSmithKline Grifols Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Menarini Merck & Co Merck KGaA Mylan Novartis Novo Nordisk Otsuka Pfizer Purdue Roche Sanofi Shionogi Shire Takeda Teva UCB Valeant Warner Chilcott Chapter 5 – Bigbiotech drug delivery deals 5.1.
    [Show full text]